Roivant Unveils Remarkable Graves’ Disease Remission Data
In a small proof-of-concept study of uncontrolled Graves’ disease, approximately 80% (17/21) of patients who completed a six-month off-treatment...
Successful ART27.13 Phase 2 Data Soars Partnering Outlook
Interim data from the Phase 2 CAReS trial reported improvements in body weight, lean body mass, and activity among...
Successful EndoQuest Paradigm Trial Procedure at AdventHealth
EndoQuest’s multicenter PARADIGM trial has moved beyond its first site, with AdventHealth Orlando completing its first colorectal endoscopic submucosal...
Artelo’s Cancer Drug Shows Promise in Phase 2 CARES Trial
Artelo’s interim Phase 2 readout in cancer anorexia-cachexia syndrome (CACS) shows patients titrated to 1300 micrograms of ART27.13 gained...
Pharma’s Next Opportunity: AI and Standardization
At Veeva R&D and Quality Summit in Boston, the pain points of managing complex processes and entering data manually...
Ascendis to Share New Rare Disease Endocrinology Data
Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning...
New Hope: Alpha Tau Treats First Pancreatic Cancer Patient
Alpha Tau has treated the first patient in IMPACT, a U.S. multi-center pilot evaluating intratumoral Alpha DaRT in combination...
Neuro Tech Triumph: Vielight Powers Sports Champions
Season-long analyses in collegiate football athletes reported decreases in diffusion MRI markers associated with neuroinflammation among players using Vielight’s...
Rezolute Aligns With FDA on Streamlined Ersodetug Trial
Rezolute secured FDA alignment to convert its ongoing upLIFT study of ersodetug in tumor-associated hyperinsulinism into a single‑arm, open‑label...
Jade Biosciences Doses First Cohort in JADE101 Phase 1 Trial
Jade Biosciences has begun dosing in a randomized, double-blind, placebo-controlled Phase 1 study of JADE101, a subcutaneous, fully human...